Healthcare Industry News: Bard
News Release - September 27, 2019
Bactiguard Signs Global License Agreement With Zimmer BiometSTOCKHOLM, Sept. 27, 2019 -- (Healthcare Sales & Marketing Network) -- Bactiguard has entered into an exclusive, global license agreement for orthopedic trauma implants with Zimmer Biomet. The agreement includes an upfront license fee of USD 3 million payable at signing, additional contingent payments of USD 2 million, based on U.S. regulatory clearance and royalties on net sales following commercialization.
"Our new, global partnership has the potential of expanding Bactiguard's current license business significantly and making a substantial contribution to our license revenues, both in the near term and in a longer perspective. It also confirms the value of the Bactiguard technology in a new application and global context, which makes me both happy and proud," says Christian Kinch, CEO.
Orthopedic trauma implants with Bactiguard's infection preventive technology were CE marked in December 2018 and will be used as a reference in the process of obtaining regulatory clearance.
According to the Orthopaedic Industry Annual Report®, the global orthopedics market was valued at USD 51 billion in 2018, where the orthopedic trauma segment accounted for 14 percent of those sales.
In 2018, Zimmer Biomet generated net sales of close to USD 8 billion. For more information about Zimmer Biomet, please visit www.zimmerbiomet.com
About Bactiguard's license business
Since 1995, Bactiguard has a successful licensing agreement with Becton, Dickinson and Company (previously C.R Bard) in the US. As a result of this successful partnership, more than 170 million Bactiguard coated Foley-catheters have been sold to date, primarily in the US and Japan.
In 2015, a license agreement for Bactiguard coated orthopaedic trauma implants, covering the ASEAN region in South East Asia, was initiated with Vigilenz Medical Devices. The implants were CE marked in December 2018 and have been approved for sales in Malaysia, where clinical evaluations are currently ongoing.
In 2017, a license agreement with Smartwise was signed in another therapeutic area, whereby drugs and other interventional therapies can be targeted and delivered to specific organs, such as the heart, lungs and the brain. This agreement generated up-front license fees of USD 2.5 million and will generate royalties when the advanced vascular injection catheters have received regulatory approval.
In 2018, a combined distribution and license agreement for China was signed with Well Lead Medical, covering the full Bactiguard product portfolio. This agreement generated initial revenues of some SEK 30 million.
The Bactiguard technology is now approved for use in the urinary tract, respiratory tract, bloodstream and on orthopaedic implants. These metal implants are intended to stay in the body for many months, up to several years and sometimes lifelong and the regulatory approval clearly shows that the technology is safe for patients.
This information is information that Bactiguard Holding AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below 2019-09-27, at. 07.30.
A telephone conference for investors, analysts and media will be held at 1.00 pm CET today, where CEO Christian Kinch and CFO Cecilia Edström will present the agreement and answer questions. The presentation for the conference call will be available at Bactiguard's website www.bactiguard.se/en/for-investors/presentations
To participate in the conference call, please dial +46-8-566-426-95
For further information, please contact:
Cecilia Edström, CFO and deputy CEO, cell phone: +46-72-226-23-28
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.